Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up

被引：0
|
作者：
Clark, R. E. [1 ]
Gambacorti-Passerini, C. [2 ]
Deininger, M. [3 ]
Mauro, M. J. [4 ]
Chuah, C. [5 ]
Kim, D. -W. [6 ]
Dyagil, I. [7 ]
Glushko, N. [8 ]
Milojkovic, D. [9 ]
Le Coutre, P. [10 ]
Garcia-Gutierrez, V. [11 ]
Crescenzo, R. [12 ]
Leip, E. [13 ]
Bardy-Bouxin, N. [14 ]
Hochhaus, A. [15 ]
Bruemmendorf, T. H. [16 ]
Cortes, J. E. [17 ]
机构：
[1] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England
[2] Univ Milano Bicocca, San Gerardo Hosp, Monza, Italy
[3] Univ Utah, Salt Lake City, UT USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore
[6] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Seoul, South Korea
[7] Natl Res Ctr Radiat Med, Kiev, Ukraine
[8] Ivano Frankivsk Reg Clin Hosp, Ivano Frankivsk, Ukraine
[9] Imperial Coll, Hammersmith Hosp, Haematol, London, England
[10] Charite Univ Med Berlin, Berlin, Germany
[11] Hosp Univ Ramon & Cajal, IRYCIS, Madrid, Spain
[12] Pfizer Inc, Collegeville, PA USA
[13] Pfizer Inc, Cambridge, MA USA
[14] Pfizer Int Operat Oncol, Paris, France
[15] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[16] Univ Klinikum RWTH Aachen, Aachen, Germany
[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
Bosutinib; Chronic myeloid leukaemia; Clinical trial;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-OR-0
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [1] Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up
    Gambacorti-Passerini, Carlo
    Deininger, Michael W.
    Mauro, Michael J.
    Chuah, Charles
    Kim, Dong-Wook
    Dyagil, Iryna
    Glushko, Natalia
    Milojkovic, Dragana
    le Coutre, Philipp D.
    Gutierrez, Valentin Garcia
    Crescenzo, Rocco J.
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andrea
    Brummendorf, Timothy H.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [2] Efficacy and Safety of Bosutinib Versus Imatinib in US Patients with Newly Diagnosed Chronic Myeloid Leukemia after 5-Years Follow-up in the Bfore Trial
    Kota, Vamsi K.
    Deininger, Michael W.
    Mendler, Jason H.
    Shen, Wei
    Goldman, Erinn Hoag
    Cortes, Jorge E.
    BLOOD, 2022, 140 : 6798 - 6799
  • [3] Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial
    Kota, Vamsi
    Deininger, Michael W.
    Mendler, Jason
    Shen, Wei
    Goldmann, Erinn
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S296 - S297
  • [4] Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
    Gambacorti-Passerini, C.
    Cortes, J. E.
    Kim, D.
    Kantarjian, H.
    Khattry, N.
    Lipton, J. H.
    Powell, C.
    Harris, P.
    Countouriotis, A. M.
    Brummendorf, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
    Cortes, Jorge E.
    Mauro, Michael J.
    Deininger, Michael W. N.
    Chuah, Charles
    Kim, Dong-Wook
    Kota, Vamsi
    Lipton, Jeffrey Howard
    Rousselot, Philippe H.
    Milojkovic, Dragana
    Le Coutre, Phillipp D.
    Gutierrez, Valentin Garcia
    Crescenzo, Rocco J.
    Leip, Eric
    An, Fiona
    Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Randomised controlled trial of compliance therapy - 18-month follow-up
    Kemp, R
    Kirov, G
    Everitt, B
    Hayward, P
    David, A
    BRITISH JOURNAL OF PSYCHIATRY, 1998, 172 : 413 - 419
  • [7] Poststroke depression -: An 18-month follow-up
    Berg, A
    Psych, L
    Palomäki, H
    Lehtihalmes, M
    Phil, L
    Lönnqvist, J
    Kaste, M
    STROKE, 2003, 34 (01) : 138 - 143
  • [8] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Charles Chuah
    Liang Piu Koh
    Tontanai Numbenjapon
    Dae Young Zang
    Kiat Hoe Ong
    Young Rok Do
    Masayuki Ohkura
    Chiho Ono
    Andrea Viqueira
    Jorge E. Cortes
    Tim H. Brümmendorf
    International Journal of Hematology, 2021, 114 : 65 - 78
  • [9] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Chuah, Charles
    Koh, Liang Piu
    Numbenjapon, Tontanai
    Zang, Dae Young
    Ong, Kiat Hoe
    Do, Young Rok
    Ohkura, Masayuki
    Ono, Chiho
    Viqueira, Andrea
    Cortes, Jorge E.
    Brummendorf, Tim H.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (01) : 65 - 78
  • [10] Endoscopic versus traditional saphenous vein harvesting: A prospective, randomized trial with 18-month follow-up
    Allen, KB
    Heimansohn, DA
    Griffith, GL
    Robison, RJ
    Schier, JJ
    Fitzgerald, EB
    Isch, JH
    Shaar, CJ
    CIRCULATION, 1999, 100 (18) : 93 - 94
12345